Seeking Alpha

Synergy Pharmaceuticals (SGYP) signs an Asset Purchase Agreement with Bristol-Myers Squibb (BMY)...

Synergy Pharmaceuticals (SGYP) signs an Asset Purchase Agreement with Bristol-Myers Squibb (BMY) to acquire the assets related to FV-100, an oral nucleoside analogue currently being developed for the treatment of shingles, a severe, painful skin rash caused by chickenpox.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs